Journal of Molecular Neuroscience

, Volume 42, Issue 1, pp 112–119 | Cite as

Functional Polymorphism in the Interleukin-6 and Interleukin-10 Genes in Patients with Paranoid Schizophrenia —A Case-Control Study

  • Monika Paul-SamojednyEmail author
  • Malgorzata Kowalczyk
  • Renata Suchanek
  • Aleksander Owczarek
  • Anna Fila-Danilow
  • Aleksandra Szczygiel
  • Jan Kowalski


Schizophrenia is a multifactorial disease with changes in immunological system. Such changes are the result of cytokine-level disturbances connected with cytokine gene polymorphisms. However, research about cytokine gene polymorphisms in schizophrenia has been surprisingly limited and ambiguous. The aim of the study was to identify whether polymorphisms of interleukin (IL)-6 and IL-10 are risk factors for the development of paranoid schizophrenia in case-control study. IL-6 (−174G/C; rs 1800795) and IL-10 (−1082G/A; rs 1800896) promoter polymorphisms in patients with paranoid schizophrenia and healthy individuals were genotyped using polymerase chain reaction–restriction fragment length polymorphism method. Differences in IL-6 and IL-10 promoter haplotypes may play an important role in determining the transcription level for IL-6 and IL-10 genes in schizophrenic patients. The presence of allele C at position −174 of IL-6 promoter sequence may correlate with increasing risk of paranoid schizophrenia in the Polish population, but research on a broadened group of people is needed. The presence of allele G at position −1082 of IL-10 promoter sequence correlates with increasing risk of paranoid schizophrenia in the Polish population. The coexistence of genotype GG at position −1082 of IL-10 promoter sequence and genotype GC at position −174 of IL-6 promoter sequence correlates with increasing risk of paranoid schizophrenia in the Polish population.


Interleukin-6 Interleukin-10 Paranoid schizophrenia Polymorphism 



We would like to thank Dr. Krzysztof Kucia for qualifying patients for the research and for collecting blood samples.


  1. Akira S, Isshiki H, Sugita T, Tanabe O, Kinoshita S, Nishio Y, Nakajima T, Hirano T, Kishimoto T (1990) A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO J 9:1897–1906PubMedGoogle Scholar
  2. Allen NC, Bagade S, McQueen MB et al (2008) Systematic meta-analysis and field synopsis of the genetic association studies in schizophrenia: the SzGene database. Nat Genet 40:827–834CrossRefPubMedGoogle Scholar
  3. Baran W, Szepietowski J, Mazur G, Baran E (2008) IL-6 and IL-10 promoter gene polymorphisms in psoriasis vulgaris. Acta Derm Venereol 88:113–116CrossRefPubMedGoogle Scholar
  4. Behrens MM, Sejnowski TJ (2009) Does schizophrenia arise from oxidative dysregulation of parvalbumin-interneurons in the developing cortex? Neuropharmacology 57(3):193–200CrossRefPubMedGoogle Scholar
  5. Blum BP, Mann JJ (2002) The GABAergic system in schizophrenia. Int J Neuropsychopharmacol 5:159–179CrossRefPubMedGoogle Scholar
  6. Boiardi L, Casali B, Farnetti E, Pipitone N, Nicoli D, Cantini F, Macchioni P, Bajocchi G, Catanoso MG, Pulsatelli L, Consonni D, Salvarani C (2006) Relationship between interleukin 6 promoter polymorphism at position −174, IL-6 serum levels, and the risk of relapse/recurrence in polymyalgia rheumatica. J Rheumatol 33:703–708PubMedGoogle Scholar
  7. Brown KD, Claudio E, Siebenlist U (2008) The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis. Arthritis Res Ther 10:212CrossRefPubMedGoogle Scholar
  8. Brull DJ, Montgomery HE, Sanders J, Dhamrait S, Luong L, Rumley A, Lowe GD, Humphries SE (2001) Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol 21:1458–1463.CrossRefPubMedGoogle Scholar
  9. Cazzulo CL, Scarone S, Grassi B, Vismara C, Trabattoni D, Clerici M (1998). Cytokines production in chronic schizophrenia patients with or without paranoid behavior. Prog Neuropsychopharmacol Biol Psychiatry 22:947–957.CrossRefGoogle Scholar
  10. Chen X, Wang X, Hossain S et al (2007) Interleukin 3 and schizophrenia: the impact of sex and family history. Mol Psychiatry 12:273–282PubMedGoogle Scholar
  11. Chiavetto LB, Boin F, Zanardini R, Popoli M, Michelato A, Bignotti S, Tura GB, Gennarelli M (2002) Association between promoter polymorphic haplotypes of interleukin-10 gene and schizophrenia. Biol Psychiatry 51:480–484CrossRefGoogle Scholar
  12. Craddock N, O’Donovan MC, Owen MJ (2005) The genetics of schizophrenia and bipolar disorder: dissecting psychosis. J Med Genet 42:193–204CrossRefPubMedGoogle Scholar
  13. Dunn AJ (2006) Effects of cytokines and infections on brain neurochemistry. Clin Neurosci Res 6:52–68CrossRefPubMedGoogle Scholar
  14. Elston RC, Forthofer R (1977) Testing for Hardy–Weinberg equilibrium in small samples. Biometrics 33:536–542CrossRefGoogle Scholar
  15. First MB, Spitzer RL, Gibbon M, Williams JBW (1997) Structured clinical interview for DSM-IV® Axis I disorders (SCID-I), clinician version. American Psychiatric Press, WashingtonGoogle Scholar
  16. García-Miss MR, Pérez-Mutul J, López-Canul B, Solís-Rodríguez F, Puga-Machado L, Oxté-Cabrera A, Gurubel-Maldonado J, Arankowsky-Sandoval G (2009) Folate, homocysteine, interleukin-6, and tumor necrosis factor alfa levels, but not the methylenetetrahydrofolate reductase C677T polymorphism, are risk factors for schizophrenia. J Psych Res doi: 10.1016/j.jpsychires.2009.10.011
  17. Hänninen K, Katila H, Saarela M, Rontu R, Mattila KM, Fan M, Hurme M, Lehtimäki T (2008) Interleukin -1 β gene polymorphism and its interactions with neuregulin-1 gene polymorphism are associated with schizophrenia. Eur Arch Psychiatry Clin Neurosci 258:10–5CrossRefPubMedGoogle Scholar
  18. Hauser J, Dmitrzak-Węglarz M (2009) In search of schizophrenia genes. Neuropsych and Neuropsychol 4(1):1–9Google Scholar
  19. Hohaus S, Giachelia M, Di Febo A, Martini M, Massini G, Vannata B, D'Alo' F, Guidi F, Greco M, Pierconti F, Larocca LM, Voso MT, Leone G (2007) Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma. Ann Oncol 18:1376–1381CrossRefPubMedGoogle Scholar
  20. Jun TY, Pae CU, Kim KS, Han H, Serretti A (2003) Interleukin-10 gene promoter polymorphism is not associated with schizophrenia in the Korean population. Psychiatry Clin Neurosci 57:153–159CrossRefPubMedGoogle Scholar
  21. Kampman O, Anttila S, Illi A, Mattila KM, Rontu R, Leinonen E, Lehtimäki T (2005) Interaction of tumor necrosis alpha - G308A and epidermal growth factor gene polymorphisms in early-onset schizophrenia. Eur Arch Psychiatry Clin Neurosci 255:279–83CrossRefPubMedGoogle Scholar
  22. Kay SR, Fiszbein A, Opler LA (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13(2):261–76PubMedGoogle Scholar
  23. Kilpinen S, Hulkkonen J, Wang XY, Hurme M (2001) The promoter polymorphism of the interleukin-6 gene regulates interleukin-6 production in neonates but not in adults. Eur Cytokine Netw 12:62–68PubMedGoogle Scholar
  24. Kimball P, Elswick RK, Shiffman M (2001) Ethnicity and cytokine production gauge response of patients with hepatitis C to interferon-alpha therapy. J Med Virol 65:510–516CrossRefPubMedGoogle Scholar
  25. Leonard B (2005) Is there an immunologic basis for schizophrenia? Expert Rev Clin Immunol 1:103–112Google Scholar
  26. Liu YL, Liu CM, Fann CS, Yang WC, Chen YH, Tseng LJ, Liu SK, Hsieh MH, Hwang TJ, Chan HY, Chen JJ, Chen WJ, Hwu HG (2010) Genetic variants of IL-6 and its receptor are not associated with schizophrenia in Taiwan. Neurosci Lett 468:330–333CrossRefPubMedGoogle Scholar
  27. Maes M, Bocchio Chiavetto L, Bignotti S, Battisa Tura G, Pioli R, Boin F, Kenis G, Bosmans E, de Jongh R, Lin A, Racagni G, Altamura CA (2000) Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. Eur Neuropsychopharmacol 10:119–24CrossRefPubMedGoogle Scholar
  28. McClellan JM, Susser E, King MC (2007) Schizophrenia: a common disease caused by multiple rare alleles. Br J Psychiatry 190:194–199CrossRefPubMedGoogle Scholar
  29. Mehler MF, Kessler JA (1998) Cytokines in brain development and function. Adv Protein Chem 52:223–251CrossRefPubMedGoogle Scholar
  30. Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003) Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27:1159–1172CrossRefPubMedGoogle Scholar
  31. Möller N, Reidel M, Ackenheil M, Schwartz MS (1999) The role of immune function in schizophrenia. An overview. Eur Arch Psychiatry Clin Neurosci 249:62–68CrossRefGoogle Scholar
  32. Monji A, Kato T, Kanaba S (2009) Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci 63:257–265CrossRefPubMedGoogle Scholar
  33. Ozbey U, Tug E, Namli M (2009) Interleukin-10 gene promoter polymorphism in patients with schizophrenia in a region of East Turkey. World J Biol Psychiatry 10(4 Pt 2):461–468Google Scholar
  34. Plata-Salaman C, Turrin N (1999) Cytokine interaction and cytokine balance in the brain: relevance to neurology and psychiatry. Mol Psych 4:302–306CrossRefGoogle Scholar
  35. Salanti G, Amountza G, Ntzani EE (2005) Hardy–Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power. Eur J Hum Genet 13:840–8CrossRefPubMedGoogle Scholar
  36. Schobitz B, de Koet ER, Sutanto W, Holsboer F (1993) Cellular localization of interleukin 6 mRNA and interleukin 6 receptor mRNA in rat brain. Eur J NeuroSci 5:1426–1435CrossRefPubMedGoogle Scholar
  37. Shalev I, Lerer E, Israel S, Uzefovsky F, Gritsenko I, Mankuta D, Ebstein RP, Kaitz M (2009) BDNF Val66Met polymorphism is associated with HPA axis reactivity to psychological stress characterized by genotype and gender interactions. Psychoneuroendocrinology 34:382–388CrossRefPubMedGoogle Scholar
  38. Shifman S, Johannesson M, Bronstein M et al (2008) Genome-wide association identifies a common variant in the reelin gene that increases the risk of schizophrenia only in women. PloS Genet 4:1–7CrossRefGoogle Scholar
  39. Singh B, Bera NK, Nayak ChR, Chaudhuri TK (2009) Decreased serum levels of interleukin-2 and interleukin-6 in Indian Bengalee schizophrenic patients. Cytokine 47:1–5CrossRefPubMedGoogle Scholar
  40. Terry CF, Loukacis V, Green FR (2000) Cooperative influence of genetic polymorphisms of interleukin 6 transcriptional regulation. J Biol Chem 275:18138–18144CrossRefPubMedGoogle Scholar
  41. Toda M, Abi-Dargham A (2007) Dopamine hypothesis of schizophrenia: making sense of it all. Curr Psychiatry Rep 9:329–336CrossRefPubMedGoogle Scholar
  42. Unfried G, Böcskör S, Endler G, Nagele F, Huber JC, Tempfer CB (2003) A polymorphism of interleukin-6 gene promoter and idiopathic reccurent miscarriage. Hum Reprod 18:267–270CrossRefPubMedGoogle Scholar
  43. Van Wagoner NJ, Oh JW, Repovic P, Benveniste EN (1999) Interleukin-6 (IL-6) production by astrocytes: autocrine regulation by IL-6 and the soluble IL-6 receptor. J Neurosci 19:5236–5244PubMedGoogle Scholar
  44. Veres A, Prohászka Z, Kilpinen S, Singh M, Füst G, Hurme M (2002) The promoter polymorphism of the IL-6 gene is associated with levels of antibodies to 60-kDa heat-shock proteins. Immunogenetics 53:851–856CrossRefPubMedGoogle Scholar
  45. Watanabe Y, Nunokawa A, Kaneko N, Muratake T, Koizumi M, Someya T (2007) Lack of association between the interleukin-1 gene complex and schizophrenia in a Japanese population. Psychiatry Clin Neurosci 61:364–369CrossRefPubMedGoogle Scholar
  46. Westendorp RG, Langermans JA, Huizinga TW, Elouali AH, Verweij CL, Boomsma DI (1997) Genetic influence on cytokine production and fatal meningococcal disease. Lancet 349:170–173CrossRefPubMedGoogle Scholar
  47. Williams JA, Pontzer CH, Shacter E (2000) Regulation of macrophage interleukin-6 (IL-6) and IL-10 expression by prostaglandin E2: the role of p38 mitogen-activated protein kinase. J Interferon Cytokine Res 20:291–298CrossRefPubMedGoogle Scholar
  48. Winterer G (2006) Cortical microcircuits in schizophrenia—the dopamine hypothesis revisited. Pharmacopsychiatry 1:68–71CrossRefGoogle Scholar
  49. Yu L, Yang MS, Zhao J, Shi YY, Zhao XZ, Yang JD, Liu ZJ, Gu NF, Feng GY, He L (2004) An association between polymorphisms of the interleukin-10 gene promoter and schizophrenia in the Chinese population. Schizophr Res 71:179–183CrossRefPubMedGoogle Scholar
  50. Zdanov A (2006) Title of chapter. In: Interleukin-10, Marincola FM (ed) National Institutes of Health, Georgetown, TX: Landes Bioscience, pp 1–10Google Scholar
  51. Zhang XY, Zhou DF, Cao LY, Wu GY, Shen YC (2005) Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics. Neuropsychopharmacology 30:1532–1538CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Monika Paul-Samojedny
    • 1
    Email author
  • Malgorzata Kowalczyk
    • 1
  • Renata Suchanek
    • 1
  • Aleksander Owczarek
    • 2
  • Anna Fila-Danilow
    • 1
  • Aleksandra Szczygiel
    • 1
  • Jan Kowalski
    • 1
  1. 1.Department of Medical GeneticsMedical University of SilesiaSosnowiecPoland
  2. 2.Division of Statistics, Department of Instrumental AnalysisMedical University of SilesiaSosnowiecPoland

Personalised recommendations